Assessment of metabolic biomarkers associated with hepatic steatosis in Crohn’s disease

Table 2 Baseline inflammatory bowel disease activity and disease-related characteristics, n (%)/median interquartile range

Variable	CD remission	Active CD	Healthy controls	Statistical significance
Previous IBD treatment	18/24 (75)	14/19 (73.7)
Clinical activity (HBI)	0 (0)	3 (0-6)		< 0.0001
Fecal calprotectin (μg/g)	45.1 (20.7-63)	331 (209-418)		< 0.0001
C-reactive protein (mg/L)	0.8 (0.5-1.6)	4.8 (1.4-8.4)	0.5 (0.5-1.9)	< 0.0001
Hemoglobin (g/dL)	14.3 (13.9-15.8)	14.6 (13.9-15.8)	14.5 (13.8-15.2)	0.07
Albumin (g/dL)	4.4 (4.2-4.5)	4.5 (4.5-4.6)	4.7 (4.4-4.8)	0.3
Endoscopic activity (SES-CD)	12 (5-13)	0 (0-3)
Ultrasound: Bowel wall thickness (mm)	2 (2-2)	4.8 (4.5-5.6)
Ultrasound: Hyperemia (Limberg score)	0 (0)	3 (2-3)
Loss of wall stratification	0 (0)	2 (13)		0.07
Mesenteric fat proliferation	0 (0)	4 (26)		0.01

CD: Crohn’s disease; IBD: Inflammatory bowel disease; HBI: Harvey-Bradshaw index; SES-CD: Simple Endoscopic Score for Crohn’s disease.